Ally Bridge Group NY LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Ally Bridge Group NY LLC
CRD #291072
SEC #801-121984
CIK #0001822947
AUM 218.9 M (2026-03-31)
Employees 7 (57% Investors, 0% Brokers)
Fees
Minimum
Phone646-829-9373
Address430 Park Avenue
New York, NY 10022
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($M)
50040030020010002010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5. Fees and Compensation

Asset-Based and Performance-Based Compensation. The fee schedules for the Clients are described in
detail in each Client’s Governing Documents.

As a general matter, the Clients pay the Adviser or its affiliates an asset-based investment management
fee each month in arrears ranging from 1.50% to 2.00% per annum based on the value of the net assets of
the respective Client on the last day of the month (the "Management Fee"). The Adviser may waive or
modify the Management Fee for investors that are members, principals, employees or affiliates of the Adviser,
relatives of such persons, and for certain investors, in the Adviser’s sole discretion.

The Adviser, or one of its affiliates serving as a general partner of a Client, is entitled to receive annual
performance-based compensation of up to 20% (the “Incentive Allocation”) from the Clients, which is
compensation that is based on a share of net capital appreciation of the assets of a Client. The Incentive
Allocation is subject to a loss carryforward provision. The Adviser, or its applicable affiliate, may waive or
modify the Incentive Allocation for investors that are members, principals, employees or affiliates of the
Adviser, relatives of such persons, and for certain large or strategic investors.

Expenses. In addition to bearing the Management Fee and Incentive Allocation, if any, the Clients are also
subject to other expenses related to its investments and operations, such as (i) professional fees (including,
without limitation, in respect of economic and other consultants and outside directors’ fees and expenses
(such as travel, lodging and meals)) incurred in connection with investments, whether or not such
investments are consummated, (including, without limitation, negotiation and due diligence costs and legal
expenses incurred in connection with workouts involving underlying portfolio companies); (ii) expenses of
purchasing, carrying and disposing of portfolio positions such as commissions, borrowing charges on
securities sold short, interest on margin accounts and other indebtedness; (iii) prime brokerage fees; (iv)
custodial fees; (v) litigation, indemnification and other extraordinary expenses, if any; (vi) legal, the cost of
negotiating side letters, related governmental and regulatory fees including, without limitation: Forms 13D,
13F, 13G, 13H, Form PF, and AIFMD Annex IV and other filings and reports the preparation and submission
of which currently or in the future may be required of a Client or the Adviser under applicable law, audit,
tax, accounting, the administrator (including middle/back office and/or independent shadow accounting
services) and anti-money laundering officer fees; (vii) market data, modeling, valuation services, order
management systems, portfolio management systems, risk management systems and/or independent risk
advisory services (including third-party software licensing, implementation, data management and recovery
services); (viii) research, including third-party research and market data (excluding the cost of terminals or
other computer hardware incorporated in the cost of obtaining such research and market data), and legal
expenses; (ix) administration fees; (x) the Management Fee; (xi) clearing costs; (xii) exchange fees; (xiii)
insurance costs, including, without limitation, errors and omissions insurance (subject to applicable law);
(xiv) brokerage fees and bank charges; (xv) marketing and related travel expenses (including any
representative fees and expenses); and (xvi) any other expenses related to the purchase, sale or transmittal

of Client assets (including, without limitation, travel directly related to portfolio management, research or
structuring of the Client’s investments).

The allocation of expenses by the Adviser between it and a Client and among Clients represents a conflict
of interest for the Adviser. The Adviser has adopted an expense allocation policy that is designed to
address this conflict. The Adviser allocates expenses to each Client in accordance with the Client’s
Governing Documents. The Adviser will seek to allocate any shared expenses for products and services
benefitting multiple Clients or both the Adviser and a Client and not covered in the Client’s Governing
Documents, in a fair and reasonable manner.

Clients incur brokerage and other transaction costs. Please see Item 12, “Brokerage Practices” below for a
discussion of certain brokerage expenses. The Adviser has no affiliated broker-dealers.
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7.      Types of Clients

The Clients consist of pooled investment vehicles. Any initial and additional subscription minimums with
respect to investment in a Client are disclosed in the Governing Documents for each Client.
Sector Form 13F Holdings Value ($M)
Praxis Precision Medicines Inc 10.6
Minerva Neurosciences Inc 10.0
OVID Therapeutics Inc 6.3
Compass Pathways PLC 5.8
Tarsus Pharmaceuticals Inc 5.7
Solid Biosciences Inc 5.5
Olivia Ventures Inc 5.3
Promis Neurosciences Inc 5.3
Edgewise Therapeutics Inc 5.1
Uniqure NV 4.9
View All
Holdings by Sector ($M)
60048036024012002021202320252027
Type Form D Funds Date Sold AUM
HF Ally Bridge Medalpha International Fund Limited [2021-06-30] 5.0 M 118.2 M
Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Ally Bridge Medalpha US Fund LP [2021-06-30] 14.0 M 3.5 M
Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
HF Ally Bridge Medalpha Master Fund LP [2019-03-28] 5.0 M 218.9 M
Filed 2025-11-14 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $100,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
AUM Breakdown Accounts AUM ($M)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 3 218.9
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 3 218.9
By Discretionary
Discretionary 3 218.9
Non-Discretionary 0 0.0
Total 3 218.9
By Non-United States Persons
Non-United States Persons 211.7
United States Persons 7.2
Total 3 218.9
Form D Directors Role # Filings # Firms 2011 - 2026
Martin Laufer Director 69 13
Christopher Lebeau Director 34 13
Jarard Blake Director 16 7
Fan Yu Director 27 4
Vimbai Gurure Director 4 4
Anna Yaeger Director 3 3
Robert Castrignano Director 4 2
Simos Simeonidis Director 3 2
Jian Xiao Director 2 2
Ally Bridge Group HK Limited Executive Officer 2 1
Ally Bridge Group Ny LLC Executive Officer 2 1
Ally Bridge Medalpha Managment LP Executive Officer 1 1
Ally Bridge Medalpha Management LP Executive Officer 1 1
Ally Bridge Medalpha General Partner LP Executive Officer 1 1
Slanix Alex Director 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001822947]
3 [0001822947]
4 [0001822947]
SC 13G [0001822947]
Form 13D/13G Filer Form 13D/13G Subject Filed
Ally Bridge Group NY LLC Cogent Biosciences Inc [2020-11-19]
Firm Profile (Form ADV)
Discretionary AUM$0.5B
Clients3 (67 non-US)
ServesInstitutional
Fund TypesHedge Fund
LEI549300OLTAFEOY6ZKY22
Form 3/4/5 Subject 2011 - 2026
Yu Fan
ABG Management Ltd
Alex Slanix Paul
Ally Bridge MedAlpha Master Fund LP
Amorfix Life Sciences Ltd
Ally Bridge Group NY LLC
ABG-WTT Global Life Science Capital Partners GP Ltd
Ally Bridge Group-WTT Global Life Science Capital Partners
MYOS RENS Technology Inc
ABG WTT-MedAvail Ltd
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Amorfix Life Sciences Ltd PMN
Common Shares
2026-02-03 Buy 700,741 $12.13 8,499,988
Amorfix Life Sciences Ltd PMN
Warrants · derivative
2026-02-03 Buy 700,741
Amorfix Life Sciences Ltd PMN
Option (right to buy) · derivative
2025-10-22 Grant 40,000 $0.00
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
2023-06-16 Other 965,130
MYOS RENS Technology Inc MDVL
Series A Warrant (Right to Buy) · derivative
2023-06-16 Other 6,818,181
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
2023-03-13 Buy 6,818,181 $0.32 2,181,818
MYOS RENS Technology Inc MDVL
Pre-Funded Warrant (Right to Buy) · derivative
2023-03-13 Buy 965,130 $0.32 308,842
MYOS RENS Technology Inc MDVL
Common Stock
2022-04-04 Buy 2,974,117 $1.06 3,152,564
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
2022-04-04 Buy 5,571,764 $1.06 5,906,070
MYOS RENS Technology Inc MDVL
Warrant (Right to Buy) · derivative
2022-04-04 Buy 1,487,058 $1.06 1,576,281
MYOS RENS Technology Inc MDVL
Common Stock
2022-04-04 Buy 11,143,529 $1.06 11,812,141
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-31 Buy 6,943 $15.00 104,145
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-31 Buy 5,727 $15.00 85,905
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-29 Buy 45 $14.00 630
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-29 Buy 55 $14.00 770
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-28 Buy 3,894 $13.98 54,438
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-28 Buy 3,213 $13.98 44,918
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-24 Buy 4,019 $13.99 56,226
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-24 Buy 4,871 $13.99 68,145
MYOS RENS Technology Inc MDVL
Common Stock
2020-12-23 Buy 9,810 $13.99 137,242
showing 20 of 39 most recent transactions
Comparable Firms State AUM
Octagon Asset Management LLC
NC 221.2 M
Triavera Capital LLC
CA 220.6 M
Incision Capital Management LP
CA 220.3 M
Sunstone Asset Management LP
NY 220.2 M
Tolis Advisors LP
NY 219.6 M
Ripple Effect Asset Management LP
NY 218.4 M
Butler Hall Capital LLC
CA 218.3 M
Jackson Hill Advisors LLC
TX 217.9 M
Oppvest LLC
NY 217.8 M
Mara River Capital Management LP
FL 217.7 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com